Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm in half starting Jan. 1 is "a day late and a dollar short," according to Raymond James, which is not expecting the move to change the trajectory of the drug launch or restore Biogen's battered reputation.